UPDATE: Goldman Sachs Upgrades Teva Pharmaceutical Industries Limited to Neutral, Raises PT to $52.00 - Teva Pharmaceutical Indus (NYSE:TEVA)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

On Wednesday, Goldman Sachs upgraded shares of Teva Pharmaceutical Industries (NYSE: TEVA) from Sell to Neutral and raised the price target from $40 to $52.Analyst Jami Rubin expects the “narrative around TEVA to change from concerns around a declining Copaxone franchise to growth and optionality in the underlying business.”Rubin went on to propose changes management could make such as:

Crypto Whales Are Loading Up — Are You?

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Cut costs
Narrow R&D focus
Divest parts of business

The analyst said mergers & acquisitions are “one of the key drivers of sector performance” and believes Teva could “put about $10bn towards deal activity.”Shares of Teva are up 1.3 percent to $50.57 in Wednesday's trading and up 26 percent year to date.